The stock of Helius Medical Technologies Inc (TSE:HSM) gapped up by $0.01 today and has $2.17 target or 7.00% above today’s $2.03 share price. The 5 months technical chart setup indicates low risk for the $170.76 million company. The gap was reported on Nov, 30 by Barchart.com. If the $2.17 price target is reached, the company will be worth $11.95 million more.
Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. About 39,100 shares traded hands. Helius Medical Technologies Inc (TSE:HSM) has risen 26.25% since April 26, 2016 and is uptrending. It has outperformed by 21.02% the S&P500.
More notable recent Helius Medical Technologies Inc (TSE:HSM) news were published by: Businesswire.com which released: “Helius Medical Technologies Rings the Opening Bell of the Toronto Stock Exchange” on June 15, 2016, also Businesswire.com with their article: “Helius Medical Technologies to Receive ISO 13485 Certificate” published on October 27, 2016, Marketwired.com published: “Helius Medical Technologies Announces Publication of Positive Results of …” on September 06, 2016. More interesting news about Helius Medical Technologies Inc (TSE:HSM) were released by: Marketwired.com and their article: “Helius Medical Announces Closing of C$9.2 Million Offering and Listing on the TSX” published on April 18, 2016 as well as Businesswire.com‘s news article titled: “Helius Medical Technologies Announces Positive Clinical Trial Results from its …” with publication date: November 02, 2015.
Helius Medical Technologies, Inc. is a medical technology firm focused on neurological wellness. The company has a market cap of $170.76 million. The Firm focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. It currently has negative earnings. The Firm is engaged in the development of its product, the portable neuromodulation stimulator device.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.